Baby Pulse Ox Monitors Get Fast-Track to Store Shelves
Published Date: 10/9/2026
Rule
Summary
The FDA is officially classifying infant pulse rate and oxygen saturation monitors for over-the-counter use as Class II devices with special safety rules. This change makes these monitors easier to get, safer to use, and less costly to bring to market. Starting October 9, 2026, parents and caregivers can expect better access to these helpful devices without extra red tape.
Analyzed Economic Effects
6 provisions identified: 5 benefits, 1 costs, 0 mixed.
OTC infant monitors moved to Class II
The FDA classified infant pulse rate and oxygen saturation monitors for over‑the‑counter use as Class II (special controls). The order is effective October 9, 2026, and the classification was applicable on November 8, 2023. FDA says this classification will reduce regulatory burdens and enhance patients' access to these devices.
Clear labeling and caregiver instructions required
Manufacturers must include labeling that tells who should (and should not) use the device, what it measures, how to interpret results and what actions to take, situations when performance may degrade, and cleaning instructions. These labeling requirements are part of the special controls listed in the final order.
Usability testing must show caregiver can use device alone
Human factors and usability testing must demonstrate that a caregiver can correctly use the device based only on the device labeling and can correctly interpret device outputs and understand next steps. These tests are required special controls for the device type.
Manufacturers must test performance across variables like skin tone
Clinical performance testing must evaluate the effect of confounding variables, such as skin pigmentation, on device performance and demonstrate consistency of outputs and evaluation of adverse events. These requirements are listed in the special controls.
Device remains subject to 510(k) premarket notification
The final order states that FDA has not determined these infant pulse rate and oxygen saturation monitors should be exempt from section 510(m), so they remain subject to premarket notification (510(k)) requirements under the Federal Food, Drug, and Cosmetic Act.
De Novo classification makes future approvals easier
Because FDA used the De Novo process to classify this device into Class II, the device can serve as a predicate for future devices, allowing other sponsors to use the less‑burdensome 510(k) pathway instead of De Novo or premarket approval. FDA states this reduces regulatory burdens for future device sponsors.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-20725, Medical Devices; Immunology and Microbiology Devices; Classification of the Hematopoietic Cell Enrichment Kit
The FDA is officially putting the hematopoietic cell enrichment kit into Class II, meaning it now has special safety rules but fewer hurdles than the highest-risk devices. This change helps make sure the kit is safe and effective while speeding up patient access to this cool medical tech. The new classification took effect on October 9, 2026, but has been in place since November 6, 2023, so manufacturers and patients can benefit now without extra costs.
Next: 2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.